DK3300729T3 - Terapeutiske sammensætninger indeholdende macitentan - Google Patents

Terapeutiske sammensætninger indeholdende macitentan Download PDF

Info

Publication number: DK3300729T3
Authority: DK; Denmark
Prior art keywords: compositions containing; therapeutic compositions; containing macitentan; macitentan; therapeutic
Prior art date: 2008-08-13

Application number

DK17191033.4T

Other languages

English (en)

Inventor

Martine Clozel

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-13

Filing date

2009-08-12

Publication date

2020-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3300729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-08-12 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2020-01-20 Application granted granted Critical

2020-01-20 Publication of DK3300729T3 publication Critical patent/DK3300729T3/da

Links

JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title 1
229960001039 macitentan Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK17191033.4T 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan DK3300729T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2008053252		2008-08-13
EP09786912.7A EP2315587B1 (en)	2008-08-13	2009-08-12	Therapeutic compositions containing macitentan

Publications (1)

Publication Number	Publication Date
DK3300729T3 true DK3300729T3 (da)	2020-01-20

Family

ID=41346591

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17191033.4T DK3300729T3 (da)	2008-08-13	2009-08-12	Terapeutiske sammensætninger indeholdende macitentan
DK09786912.7T DK2315587T3 (da)	2008-08-13	2009-08-12	Terapeutiske sammensætninger indeholdende macitentan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK09786912.7T DK2315587T3 (da)	2008-08-13	2009-08-12	Terapeutiske sammensætninger indeholdende macitentan

Country Status (30)

Country	Link
US (3)	US8809334B2 (da)
EP (2)	EP2315587B1 (da)
JP (3)	JP5764061B2 (da)
KR (1)	KR101678699B1 (da)
CN (1)	CN102099026B (da)
AR (1)	AR073031A1 (da)
AU (1)	AU2009280843B2 (da)
BR (1)	BRPI0917661B8 (da)
CA (1)	CA2731370C (da)
CY (2)	CY1119826T1 (da)
DK (2)	DK3300729T3 (da)
ES (2)	ES2763176T3 (da)
HK (1)	HK1253355B (da)
HR (2)	HRP20171917T1 (da)
HU (2)	HUE036071T2 (da)
IL (1)	IL211143A0 (da)
LT (2)	LT3300729T (da)
MA (1)	MA32614B1 (da)
MX (1)	MX350011B (da)
MY (1)	MY178894A (da)
NO (1)	NO2315587T3 (da)
NZ (1)	NZ591601A (da)
PL (2)	PL2315587T3 (da)
PT (2)	PT3300729T (da)
RU (1)	RU2519161C2 (da)
SI (2)	SI2315587T1 (da)
SM (2)	SMT201700592T1 (da)
TW (1)	TWI446911B (da)
WO (1)	WO2010018549A2 (da)
ZA (1)	ZA201101900B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2393117T3 (es)	2005-09-12	2012-12-18	Actelion Pharmaceuticals Ltd.	Composición farmacéutica estable que comprende una pirimidina-sulfamida
MX2010001837A (es)	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
EP2246336B1 (en)	2008-02-28	2020-07-01	Nippon Shinyaku Co., Ltd.	Fibrosis inhibitor
MX350011B (es)	2008-08-13	2017-08-22	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas que contienen macitentan.
EP3712142B1 (en)	2013-01-11	2022-07-06	Corsair Pharma, Inc.	Prodrugs of treprostinil
US9505737B2 (en)	2013-01-11	2016-11-29	Corsair Pharma, Inc.	Treprostinil derivative compounds and methods of using same
US9394227B1 (en)	2015-06-17	2016-07-19	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en)	2015-06-17	2017-05-09	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en)	2016-04-29	2017-10-17	Corning Optical Communications Wireless Ltd	Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
EP3554507A1 (en)	2016-12-14	2019-10-23	Respira Therapeutics, Inc.	Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US20200085741A1 (en) *	2018-09-14	2020-03-19	Pharmosa Biopharm Inc.	Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
EP3897646B1 (en) *	2018-12-21	2024-05-22	Actelion Pharmaceuticals Ltd	Macitentan for the treatment of pulmonary arterial hypertension
TW202042818A (zh)	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
IL293271A (en)	2019-11-29	2022-07-01	Actelion Pharmaceuticals Ltd	Methods for treating pulmonary artery hypertension
JP2023507626A (ja)	2019-12-16	2023-02-24	テナックス・セラピューティクス，インコーポレイテッド	駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
EP4456897A4 (en)	2021-12-31	2025-12-10	Tenax Therapeutics Inc	ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4539333A (en)	1976-05-11	1985-09-03	Burroughs Wellcome Co.	Prostacyclin, methods of using and method of making
DE2845770A1 (de)	1978-10-19	1980-04-30	Schering Ag	Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja)	1982-01-20	1983-07-25	Toray Ind Inc	５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en)	1984-03-08	1987-07-28	The Upjohn Company	Interphenylene carbacyclin derivatives
EP1693372A1 (en) *	2000-12-18	2006-08-23	Actelion Pharmaceuticals Ltd.	Novel Sulfamides and their use as endothelin receptor antagonists
BR0115995A (pt) *	2000-12-19	2004-01-13	Merck Patent Gmbh	Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
DE10100426B4 (de)	2001-01-08	2006-04-06	Steag Hamatech Ag	Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (da) *	2001-04-26	2009-10-21	Nippon Shinyaku Co Ltd
WO2004017993A1 (en) *	2002-08-12	2004-03-04	Actelion Pharmaceuticals Ltd	Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
NZ540937A (en)	2002-12-02	2008-06-30	Actelion Pharmaceuticals Ltd	Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US20050101608A1 (en) *	2003-09-24	2005-05-12	Santel Donald J.	Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) *	2004-11-11	2006-08-16	Actelion Pharmaceuticals Ltd	Novel sulfamides
ES2393117T3 (es) *	2005-09-12	2012-12-18	Actelion Pharmaceuticals Ltd.	Composición farmacéutica estable que comprende una pirimidina-sulfamida
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
MX2010008994A (es)	2008-02-20	2010-09-07	Actelion Pharmaceuticals Ltd	Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
MX350011B (es)	2008-08-13	2017-08-22	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas que contienen macitentan.

2009
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
- 2009-08-12 SM SM20170592T patent/SMT201700592T1/it unknown
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja not_active Expired - Fee Related
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active Active
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh not_active Expired - Fee Related
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en not_active Revoked
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en not_active Revoked
- 2009-08-12 SM SM20190740T patent/SMT201900740T1/it unknown
- 2009-08-12 HR HRP20171917TT patent/HRP20171917T1/hr unknown
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt not_active IP Right Cessation
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/da active
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en not_active Ceased
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
2015
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/en not_active IP Right Cessation
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown

Also Published As

Publication number	Publication date
MY178894A (en)	2020-10-21
WO2010018549A3 (en)	2010-07-29
JP5956026B2 (ja)	2016-07-20
US9173881B2 (en)	2015-11-03
SI3300729T1 (sl)	2020-02-28
PL2315587T3 (pl)	2018-03-30
BRPI0917661B1 (pt)	2019-12-17
HUE036071T2 (hu)	2018-06-28
JP5764061B2 (ja)	2015-08-12
CY1122641T1 (el)	2021-03-12
EP3300729A1 (en)	2018-04-04
AU2009280843A1 (en)	2010-02-18
TW201010985A (en)	2010-03-16
US20140329824A1 (en)	2014-11-06
CN102099026B (zh)	2012-08-29
PL3300729T3 (pl)	2020-04-30
NO2315587T3 (da)	2018-03-24
AR073031A1 (es)	2010-10-06
JP2015180683A (ja)	2015-10-15
ES2652590T3 (es)	2018-02-05
JP5956025B2 (ja)	2016-07-20
JP2011530581A (ja)	2011-12-22
EP2315587B1 (en)	2017-10-25
DK2315587T3 (da)	2018-01-02
JP2015187148A (ja)	2015-10-29
HUE047767T2 (hu)	2020-05-28
CA2731370C (en)	2017-03-14
US9597331B2 (en)	2017-03-21
HRP20192204T1 (hr)	2020-03-06
US8809334B2 (en)	2014-08-19
PT3300729T (pt)	2020-01-20
MX2011001625A (es)	2011-03-29
EP2315587A2 (en)	2011-05-04
RU2011109084A (ru)	2012-09-20
KR101678699B1 (ko)	2016-11-23
RU2519161C2 (ru)	2014-06-10
ZA201101900B (en)	2012-08-29
MX350011B (es)	2017-08-22
SI2315587T1 (en)	2018-04-30
US20110136818A1 (en)	2011-06-09
WO2010018549A2 (en)	2010-02-18
LT2315587T (lt)	2018-01-10
ES2763176T3 (es)	2020-05-27
KR20110045006A (ko)	2011-05-03
CA2731370A1 (en)	2010-02-18
MA32614B1 (fr)	2011-09-01
LT3300729T (lt)	2020-01-10
IL211143A0 (en)	2011-04-28
AU2009280843B2 (en)	2015-03-05
HK1253355B (en)	2020-06-19
US20160022678A1 (en)	2016-01-28
HK1253355A1 (en)	2019-06-14
SMT201900740T1 (it)	2020-01-14
EP3300729B1 (en)	2019-10-09
HRP20171917T1 (hr)	2018-02-09
CN102099026A (zh)	2011-06-15
NZ591601A (en)	2012-12-21
SMT201700592T1 (it)	2018-03-08
BRPI0917661B8 (pt)	2021-05-25
BRPI0917661A2 (pt)	2015-12-01
PT2315587T (pt)	2018-01-31
CY1119826T1 (el)	2018-06-27
TWI446911B (zh)	2014-08-01

Publication	Publication Date	Title
BRPI1011587A2 (pt)	2016-03-22	compostos e composições terapèuticas
DK2634232T3 (da)	2022-06-07	Sammensætninger
BRPI0906749A2 (pt)	2015-07-07	Composição
BRPI0913808A2 (pt)	2017-06-20	composição
DE602008002756D1 (de)	2010-11-04	Bauzusammensetzung
ES2628203T8 (es)	2021-08-23	Composiciones antitranspirantes
ME01423B (me)	2013-12-20	Fungicidni sastavi
BRPI0914746A2 (pt)	2019-09-24	composições fungicidas
HUE059171T2 (hu)	2022-10-28	Kompozíciók
BRPI0917231A2 (pt)	2015-11-10	composição
IT1392101B1 (it)	2012-02-09	Composizione comprendente isoflavoni
FR2933868B1 (fr)	2012-08-17	Compositions cosmetiques
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
EP2335669A4 (en)	2016-05-11	COMPOSITION FOR MEANS FOR DESENSIBILIZING TEETH
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
IL211143A0 (en)	2011-04-28	Therapeutic compositions containing macitentan
BRPI0921313A2 (pt)	2015-12-29	composição farmaucêutica
EP2357204A4 (en)	2012-06-27	COMPOSITION
BRPI0912171A2 (pt)	2017-10-31	composição farmacêutica
EP2249776A4 (en)	2014-01-08	SHOWER COMPOSITIONS
BRPI0921301A2 (pt)	2015-12-29	composição farmacêutica
BRPI0917584A2 (pt)	2015-11-17	composição
BRPI0909764A2 (pt)	2015-10-06	compostos terapêuticos
EP2356973A4 (en)	2015-03-04	COSMETIC COMPOSITION